ATAGI advised on 25th March 2021 that there was a potential safety concern being investigated overseas, involving cases of thrombosis (blood clots) and thrombocytopenia (low blood platelet count) occurring after COVID-19 Vaccine AstraZeneca.
On 2 April 2021 ATAGI reported that a probable case had been reported in an Australian vaccine recipient, and issued an updated advice for healthcare providers.
This ‘thrombosis with thrombocytopenia syndrome’ (TTS) is a newly described serious condition, with unusual blood clots in the brain (cerebral venous sinus thrombosis) or in other parts of the body, associated with low platelet levels.
Read more on health.gov.au